Candesartan cilexetil: An update

Alexander Joost, Heribert Schunkert, Peter Walter Radke*

*Korrespondierende/r Autor/-in für diese Arbeit
3 Zitate (Scopus)

Abstract

Introduction: Candesartan cilexetil is one of the most often-used first-line drugs regarding the management of arterial hypertension. Moreover, this drug has proven its effectiveness in chronic heart failure and exerts beneficial effects in diabetes, stroke, dementia and atrial fibrillation. Areas covered: This review focuses on the use of candesartan cilexetil in Phase II and Phase III trials and their implications for clinical usage in the treatment of arterial hypertension and heart failure. The usage of candesartan cilexetil in patients with stroke, migraine or atrial fibrillation, hypertrophy obstructive or nonobstructive cardiomyopathy and diabetic or non diabetic renal diseases will be discussed. Relevant publications were identified by an extensive Medline search. Expert opinion: Candesartan cilexetil is a highly effective ARB for the treatment of arterial hypertension and heart failure. Also, recent trials have suggested beneficial effects in diabetic patients, patients with nondiabetic renal diseases, stroke, migraine and atrial fibrillation.

OriginalspracheEnglisch
ZeitschriftExpert Opinion on Pharmacotherapy
Jahrgang12
Ausgabenummer11
Seiten (von - bis)1769-1780
Seitenumfang12
ISSN1465-6566
DOIs
PublikationsstatusVeröffentlicht - 01.08.2011

Fingerprint

Untersuchen Sie die Forschungsthemen von „Candesartan cilexetil: An update“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren